OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Metrics to compare | 226950 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship226950PeersSector | |
---|---|---|---|---|
P/E Ratio | −25.9x | −7.6x | −0.6x | |
PEG Ratio | 0.26 | −0.06 | 0.00 | |
Price/Book | 51.4x | 3.1x | 2.6x | |
Price / LTM Sales | 155.0x | 9.9x | 3.3x | |
Upside (Analyst Target) | - | 45.8% | 39.1% | |
Fair Value Upside | Unlock | 11.7% | 5.4% | Unlock |